Evidence map›Paper›PMID 38028197›Full record

ArticleMolecular therapy. Nucleic acids2023

Efficacy of exon-skipping therapy for DMD cardiomyopathy with mutations in actin binding domain 1.

Naoko Shiba, Xiao Yang, Mitsuto Sato, Shin Kadota, Yota Suzuki, Masahiro Agata, Kohei Nagamine, Masaki Izumi, Yusuke Honda, Tomoya Koganehira and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Investigating theBioconjugate chemistry · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Naoko ShibaDepartment of Regenerative Science and Medicine, Shinshu University, Matsumoto 390-8621, Japan.
Xiao YangDepartment of Regenerative Science and Medicine, Shinshu University, Matsumoto 390-8621, Japan.
Mitsuto SatoDepartment of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto 390-8621, Japan.
Shin KadotaDepartment of Regenerative Science and Medicine, Shinshu University, Matsumoto 390-8621, Japan.
Yota SuzukiDepartment of Regenerative Science and Medicine, Shinshu University, Matsumoto 390-8621, Japan.
Masahiro AgataDepartment of Regenerative Science and Medicine, Shinshu University, Matsumoto 390-8621, Japan.
Kohei NagamineDepartment of Regenerative Science and Medicine, Shinshu University, Matsumoto 390-8621, Japan.
Masaki IzumiDepartment of Regenerative Science and Medicine, Shinshu University, Matsumoto 390-8621, Japan.
Yusuke HondaDepartment of Regenerative Science and Medicine, Shinshu University, Matsumoto 390-8621, Japan.
Tomoya KoganehiraDepartment of Regenerative Science and Medicine, Shinshu University, Matsumoto 390-8621, Japan.
Hideki KobayashiDepartment of Regenerative Science and Medicine, Shinshu University, Matsumoto 390-8621, Japan.
Hajime IchimuraDepartment of Regenerative Science and Medicine, Shinshu University, Matsumoto 390-8621, Japan.
Shinichiro ChumaDepartment of Regeneration Science and Engineering, Institute for Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
Junichi NakaiGraduate Schools of Dentistry, Tohoku University, Sendai 980-8575, Japan.
Shugo TohyamaDepartment of Cardiology, Keio University School of Medicine, Tokyo 160-8582, Japan.
Keiichi FukudaDepartment of Cardiology, Keio University School of Medicine, Tokyo 160-8582, Japan.
Daigo MiyazakiDepartment of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto 390-8621, Japan.
Akinori NakamuraDepartment of Clinical Research, National Hospital Organization Matsumoto Medical Center, Matsumoto 399-8701, Japan.
Yuji ShibaDepartment of Regenerative Science and Medicine, Shinshu University, Matsumoto 390-8621, Japan.
Shinshu University · JPKeio University · JPKyoto University · JPMatsumoto City Hospital · JPTohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exon-skipping therapy is a promising treatment strategy for Duchenne muscular dystrophy (DMD), which is caused by loss-of-function mutations in the

Indexed as

actin-binding domainantisense oligonucleotide-mediated exon skippingCaMKIIcardiomyopathydesminDuchenne muscular dystrophydystrophinhiPSC-CMsMT: oligonucleotides: therapies and applications

Identifiers

PMID38028197
PMCPMC10654596
OpenAlexW4387767123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.